Document ID: chunk:federal_register_of_legislation:F2025L00062:schedule:1:p47
Version: federal_register_of_legislation:F2025L00062
Segment Type: schedule
Provision Reference: sch 1 (pt 47/51)
Character Range: 145868–151163

practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner, (iii) an endorsed midwife where patient care is being shared with a medical practitioner.
C16270  P16270  CN16270  Selpercatinib                   Locally advanced or metastatic non-small cell lung cancer                                                                                                                                                                                                                                                                                                                                                                                    Compliance with Authority Required procedures - Streamlined Authority Code 16270
                                                         The condition must have evidence of rearranged during transfection (RET) gene fusion in tumour material - this evidence has been obtained prior to commencing treatment with this drug; AND
                                                         Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score of no higher than 2 at treatment initiation; AND
                                                         The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication; AND
                                                         Patient must be initiating treatment with this drug. or
                                                         Patient must be continuing treatment with this drug, with an absence of further disease progression while being treated with this drug.
                                                         Medical practitioners must prescribe the appropriate quantities of appropriate strength(s) to provide sufficient drug, based on the weight of the patient, adequate for 4 weeks per dispensing, according to the specified dosage in the approved Therapeutic Goods Administration (TGA) Product Information (PI). A separate authority prescription form must be completed for each strength requested.
C16273  P16273  CN16273  Methyldopa                      Hypertension                                                                                                                                                                                                                                                                                                                                                                                                                                 Compliance with Authority Required procedures
                                                         Patient must be pregnant;
                                                         Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner, an endorsed midwife who is each of: (a) sharing patient care with a medical practitioner for the current pregnancy episode, (b) continuing existing treatment with this drug that was initiated by a medical practitioner.
C16274  P16274  CN16274  Methylphenidate                 Attention deficit hyperactivity disorder                                                                                                                                                                                                                                                                                                                                                                                                     Compliance with Authority Required procedures
                                                         Patient must have demonstrated a response to immediate-release methylphenidate hydrochloride with no emergence of serious adverse events; AND
                                                         Patient must require continuous coverage over 12 hours; AND
                                                         The treatment must not exceed a maximum daily dose of 72 mg of PBS-subsidised treatment with this drug;
                                                         Patient must be or have been diagnosed between the ages of 6 and 18 years inclusive.
C16276  P16276  CN16276  Oxycodone                       Severe pain
                         Tramadol                        The treatment must be for short term therapy of acute severe pain; AND
                                                         Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid analgesics; or
                                                         Patient must be unable to use non-opioid analgesics due to contraindications or intolerance; AND
                                                         Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner, (iii) an endorsed midwife who is sharing the post-operative care of the patient with a medical practitioner.
C16279  P16279  CN16279  Temazepam                       For prescribing by certain health practitioners
                                                         Must be treated by a health practitioner who is